US2003108537A1PendingUtilityA1
Dietary supplement enhancing the muscular energy metabolism, comprising an alkanoyl carnitine and ribosee
Priority: Jun 14, 2000Filed: Jan 6, 2001Published: Jun 12, 2003
Est. expiryJun 14, 2020(expired)· nominal 20-yr term from priority
Inventors:Pietro Pola
A61P 9/00A61P 43/00A61P 3/02A61P 21/04A23V 2002/00A61K 31/7004A23L 33/15A23L 33/175A61K 31/205A23L 27/30A61K 45/06A23L 33/13C07H 3/02
40
PatentIndex Score
0
Cited by
0
References
0
Claims
Abstract
A health food/dietary supplement is disclosed suitable for enhancing muscular energy metabolism, comprising as its characterising active ingredients an alkanoyl L-carnitine and ribose.
Claims
exact text as granted — not AI-modified1 . A food/dietary supplement which comprises the following characterizing ingredients:
(a) an alkanoyl L-carnitine selected from the group comprising isovaleryl L-carnitine, propionyl L-carnitine or the pharmacologically acceptable salts thereof or mixtures thereof; and (b) ribose or a phosphorylate derivative thereof.
2 . The supplement of claim 1 , further comprising:
(c) a “carnitine” selected from the group comprising L-carnitine, acetyl L-carnitine, butyryl L-carnitine and valeryl L-carnitine or the pharmacologically acceptable salts or mixtures thereof.
3 . The supplement of anyone of the preceding claims which further comprises vitamins, sugars, coenzymes, mineral substances, aminoacids, peptides and antioxidants.
4 . The supplement of any of the preceding claims wherein the pharmacologically acceptable salt is selected from the group comprising: chloride; bromide; iodide; aspartate, acid aspartate; citrate, acid citrate; tartrate; phosphate, acid phosphate; fumarate, acid fumarate; glycerophosphate; glucose phosphate; lactate; maleate, acid maleate; mucate; orotate; oxalate; acid oxalate; sulphate, acid sulphate; trichloroacetate; trifluoroacetate and methane sulphonate.
5 . The supplement of any of the preceding claims, for the prevention of myocardial insufficiency and in post-infarct conditions, psychomotor alterations and to cope with the increased muscular energy requirements.
6 . A food/dietary supplement in solid, semi-solid or liquid form.
7 . The food/dietary supplement of any of the preceding claims in the form of tablets, capsules, lozenges, pills, granulates, creams, syrups or drops.
8 . The supplement of any of the preceding claims, wherein the weight ratio of ingredients (a):(b):(c) ranges from 1:1:1 to 1:10:2.
9 . The supplement of claim 8 , in unit dosage form, comprising:
Propionyl L-carnitine
125 mg
Acetyl L-carnitine
125 mg
L-carnitine
125 mg
Isovaleryl L-carnitine
125 mg
Ribose
500 mg
10 . The supplement of claim 8 , in unit dosage form, comprising:
Propionyl L-carnitine
250
mg
Acetyl L-carnitine
250
mg
Isovaleryl L-carnitine
250
mg
L-carnitine
250
mg
Ribose
2
g
Ribonucleic acid
100
mg
Deoxyribonucleic acid
100
mg
11 . The supplement of claim 8 , in unit dosage form, comprising:
Propionyl L-carnitine
250
mg
Acetyl L-carnitine
250
mg
Isovaleryl L-carnitine
250
mg
L-carnitine
250
mg
Ribose
2
g
L-glutamine
100
mg
L-alanine
100
mg
L-arginine
100
mg
L-glicine
100
mg
L-histidine
100
mg
L-isoleucine
100
mg
L-phenylalanine
50
mg
L-threonine
50
mg
L-serine
100
mg
12 . The supplement of claim 8 , in unit dosage form, comprising:
Propionyl L-carnitine
250
mg
Acetyl L-carnitine
250
mg
Isovaleryl L-carnitine
250
mg
L-carnitine
250
mg
Ribose
1
g
Glucose-1,6-diphosphate
200
mg
Fructose-1,6-diphosphate
200
mg
Galactose-1,6-phosphate
200
mg
Glycerol-3-phosphate
200
mg
Phosphenylpyruvate
100
mg
Thiamine pyrophosphate
5
mg
Pyridoxal-5-phosphate
5
mg
Magnesium stearate
2
mg
13 . The supplement of claim 8 , in unit dosage form, comprising:
Propionyl L-carnitine
250
mg
Acetil L-carnitine
250
mg
Isovaleryl L-carnitine
250
mg
L-carnitine
250
mg
Ribose
1
g
Vit. A
1250
U.I.
Vit. B 1
0.5
mg
Vit. B 6
30
mg
Vit. C
50
mg
Vit. E
5
mg
Nicotinamide
25
mg
Vit. B 12
100
mcg
Vit. D
100
U.I.
Pantothenic acid
30
mg
Magnesium glycinate
5
mg
Manganese
1
mg
L-Selenomethionine
50
mcg
Molybdenum
10
mcg
Zinc
1
mg
14 . A method for the prevention and/or treatment of states of myocardial or skeletal muscle dysfunction related to conditions of anoxia or insufficient energy supply as occurring in coronary or post-infarct disorders or during prolonged physical activity and muscle fatigue, which comprises administering to an individual in need thereof a combination composition comprising the following ingredients:
(a) an alkanoyl L-carnitine selected from the group comprising isovaleryl L-carnitine, propionyl L-carnitine or the pharmacologically acceptable salts thereof or mixtures thereof, and (b) ribose or a phosphorylate derivative thereof.Join the waitlist — get patent alerts
Track US2003108537A1 — get alerts on status changes and closely related new filings.
We store only your email — no account needed. See our privacy policy.